Nexalin Technology Inc NXL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $4.32
- Day Range
- $3.97–4.34
- 52-Week Range
- $3.97–60.00
- Bid/Ask
- $4.00 / $4.68
- Shares Outstanding
- 829,400.00
- Market Cap
- $3.41M
- Volume/Avg
- 428,337 / 983,695
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.22
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.nexalin.com
Valuation
|
Metric
|
NXL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.98 |
Price/Sales | 12.22 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NXL
|
|---|---|
Quick Ratio | 0.71 |
Current Ratio | 1.25 |
Interest Coverage | — |
Quick Ratio
NXL
Profitability
|
Metric
|
NXL
|
|---|---|
Return on Assets (Normalized) | −136.62% |
Return on Equity (Normalized) | −166.56% |
Return on Invested Capital (Normalized) | −166.62% |
Return on Assets
NXL
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|h$crzV? | LOCK|jZqw | $170B | |||
| Medtronic PLC
MDT
| LOCK|kF<C?&k | LOCK|rQ^% | $112B | |||
| Stryker Corp
SYK
| LOCK|d!ChLL< | LOCK|k< | $106B | |||
| Boston Scientific Corp
BSX
| LOCK|HRb$F<r | LOCK|$<<?l | $61B | |||
| Edwards Lifesciences Corp
EW
| LOCK|p%$v$<WD | LOCK|m^gKq | $49B | |||
| DexCom Inc
DXCM
| LOCK|<<<%$Fnk | LOCK|K@#$? | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|&?<r$^Q | LOCK|><d | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|<< | LOCK|#&@ | $24B | |||
| Steris PLC
STE
| LOCK|v>Jh@xy | LOCK|gkh& | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|m^T@Lt$ | LOCK|Hz$ | $17B |
United States